Down another 6% in a week! So will the GSK share price ever recover?

The GSK share price has had a rotten few years and now it’s heading south yet again. Investor Harvey Jones continues to hang on in the hope that it will recover.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: GSK plc

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GSK (LSE: GSK) share price is a nightmare and there’s little sign of respite for long-suffering investors.

Shares in the FTSE 100 pharmaceutical giant now trade 10.18% lower than five years ago. The misery continues, with the stock falling 5.97% last week. As a benchmark, it’s up just 1.47% over the last 12 months.

Should you invest £1,000 in Gsk right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Gsk made the list?

See the 6 stocks

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

I thought the stock looked great value when I bought it earlier this year, but like many before me, I’ve been faced with a reality check. So what’s going on?

Why are the shares falling and falling?

I remember the glory days when, as GlaxoSmithKline, this was widely viewed as the ultimate buy-and-hold income and growth stock.

One FTSE 100 pharma stock has delivered on its long-term potential. Unfortunately, it isn’t GSK, but rival AstraZeneca.

I’m not sure Astra even sees GSK as rival these days. Astra is now the UK’s largest company with a market cap north of £180bn. GSK is worth just a third of that at £60bn.

Like every pharmaceutical company, GSK has seen patents expire on a string of blockbuster drugs, allowing generic rivals to eat into revenues. Unlike Astra, it has struggled to offset these losses with new, high-revenue products.

CEO Emma Walmsley has worked hard to replenish its drugs pipeline, but it’s proving a struggle. To fund GSK’s R&D efforts she froze the dividend at 80p per share for yonks. In 2022, it was slashed to 44p then to 42p the year after.

Spinning off its consumer healthcare division as Haleon in 2022 was supposed to sharpen GSK’s focus on pharmaceuticals and vaccines. All it’s done is encourage investors to focus on its weaknesses instead.

Fallen FTSE 100 dividend hero

Brokers are optimistic though. They’ve set an average one-year share price target of 1,905.5p. If GSK hits that, it would mark a rise of 24% from today’s 1,535p.

The forecast yield of 3.61% is bang in line with the FTSE 100 average of 3.54%. While that’d down from the 5.5% some will remember, shareholder payouts are covered 2.6 times by earnings, which offers scope for growth.

I haven’t even mentioned the big cloud hanging over GSK: ongoing US litigation over its discontinued heartburn blockbuster drug Zantac. The shares plunged almost 10% on 3 June after a Delaware judge allowed more than 70,000 lawsuits alleging it caused cancer.

GSK is confident of its case. It notes that since 2019, 16 epidemiological studies have examined the potential cancer link and found none. Last week, it announced confidential settlements in two lawsuits filed in California involving colorectal cancer. There are plenty more left.

There’s no way I’m buying more GSK shares while this hangs over the stock. I won’t sell, either, so all I can do is hang on grimly. Even if GSK gets the right result, I’m not convinced its shares the best use of my money today. But for now, I’m stuck with them.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has positions in GSK. The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Pound coins for sale — 51 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Elevated view over city of London skyline
Investing Articles

The M&G dividend yields over 10% — and could get higher!

Christopher Ruane explains why he's upbeat about the long-term outlook for the M&G dividend yield and would happily buy the…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

2 popular UK growth stocks I wouldn’t touch with a bargepole in today’s market

Buying growth stocks can deliver market-beating returns, but this FTSE 250 pair doesn't look like a convincing investment for our…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

10 FTSE shares falling today after President Trump’s tariffs bombshell!

Our writer explains why JD Sports Fashion from the FTSE 100 and a diverse bunch of other UK stocks are…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

With value investing back in vogue, I’m taking a leaf out of Warren Buffett’s playbook

With tariffs and trade wars resulting in heightened market volatility, Andrew Mackie takes comfort in Warren Buffett’s words of wisdom.

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Around a 1-year high, is there enough value left in Next’s share price to make it worth me buying?

Next’s share price has risen a lot in eight months, but there could still be a lot of value left…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

OMG DYOR but IMO this ‘cool’ FTSE 100 stock offers bangin’ VFM!

Despite being one of the least trendy 50-somethings around, our writer considers how Gen Z could help push this FTSE…

Read more »

Investing Articles

2 cheap FTSE 100 and FTSE 250 growth stocks to consider as stock markets sink

I think these Footsie and FTSE 250 growth shares could be very shrewd buys to consider in the current climate.…

Read more »

Investing Articles

3 shares I’ve bought in the 2025 stock market sell-off

The stock market has experienced a lot of turbulence in recent weeks. Edward Sheldon has been taking advantage and buying…

Read more »